Oluwole Adeyemi Babatunde1,2, Jan M Eberth3, Tisha M Felder4, Robert Moran3, Chanita Hughes-Halbert5, Samantha Truman3, James R Hebert3,4,6, Sue Heiney4, Swann Arp Adams3,4. 1. Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, 29425, USA. babatund@musc.edu. 2. Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, 915 Greene Street, Columbia, SC, 29208, USA. babatund@musc.edu. 3. Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, 915 Greene Street, Columbia, SC, 29208, USA. 4. College of Nursing, University of South Carolina, 1601 Greene Street, Columbia, SC, 29208, USA. 5. Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, 29425, USA. 6. Connecting Health Innovations LLC, 1417 Gregg Street, Columbia, SC, 29201, USA.
Abstract
OBJECTIVES: Diagnosis-to-treatment interval is an important quality measure that is recognized by the National Accreditation Program for Breast Centers, and the American Society of Breast Surgeons and the National Quality Measures for Breast Care. The aim of this study was to assess factors related to delays in receiving breast cancer treatment. METHODS: This retrospective cohort study (2002 to 2010) used data from the South Carolina Central Cancer Registry (SCCCR) and Office of Revenue and Fiscal Affairs (RFA) to examine racial differences in diagnosis-to-treatment time (in days), with adjuvant hormone receipt, surgery, chemotherapy, and radiotherapy assessed separately. Chi-square tests, and logistic regression and generalized linear models were used to compare diagnosis-to-treatment days. RESULTS: Black women on average received adjuvant hormone therapy, surgery, chemotherapy, and radiotherapy 25, 8, 7, and 3 days later than their White counterparts, respectively. Black women with local stage cancer had later time to surgery (OR: 1.6; CI: 1.2-2.2) compared with White women with local stage cancer. Black women living in rural areas had higher odds (OR: 2.0; CI: 1.1-3.7) of receiving late chemotherapy compared with White women living in rural areas. Unmarried Black women also had greater risk (OR: 2.0; CI: 1.0-4.0) of receiving late radiotherapy compared to married White women. CONCLUSIONS: To improve timely receipt of effective BrCA treatments, programs aimed at reducing racial disparities may need to target subgroups of Black breast cancer patients based on their social determinants of health and geographic residence.
OBJECTIVES: Diagnosis-to-treatment interval is an important quality measure that is recognized by the National Accreditation Program for Breast Centers, and the American Society of Breast Surgeons and the National Quality Measures for Breast Care. The aim of this study was to assess factors related to delays in receiving breast cancer treatment. METHODS: This retrospective cohort study (2002 to 2010) used data from the South Carolina Central Cancer Registry (SCCCR) and Office of Revenue and Fiscal Affairs (RFA) to examine racial differences in diagnosis-to-treatment time (in days), with adjuvant hormone receipt, surgery, chemotherapy, and radiotherapy assessed separately. Chi-square tests, and logistic regression and generalized linear models were used to compare diagnosis-to-treatment days. RESULTS: Black women on average received adjuvant hormone therapy, surgery, chemotherapy, and radiotherapy 25, 8, 7, and 3 days later than their White counterparts, respectively. Black women with local stage cancer had later time to surgery (OR: 1.6; CI: 1.2-2.2) compared with White women with local stage cancer. Black women living in rural areas had higher odds (OR: 2.0; CI: 1.1-3.7) of receiving late chemotherapy compared with White women living in rural areas. Unmarried Black women also had greater risk (OR: 2.0; CI: 1.0-4.0) of receiving late radiotherapy compared to married White women. CONCLUSIONS: To improve timely receipt of effective BrCA treatments, programs aimed at reducing racial disparities may need to target subgroups of Black breast cancer patients based on their social determinants of health and geographic residence.
Authors: Stacey A Fedewa; Stephen B Edge; Andrew K Stewart; Michael T Halpern; Nicole M Marlow; Elizabeth M Ward Journal: J Health Care Poor Underserved Date: 2011-02
Authors: Muin J Khoury; Scott Bowen; W David Dotson; Emily Drzymalla; Ridgely F Green; Robert Goldstein; Katherine Kolor; Leandris C Liburd; Laurence S Sperling; Rebecca Bunnell Journal: Genet Med Date: 2022-04-28 Impact factor: 8.864
Authors: Oluwole Adeyemi Babatunde; Whitney E Zahnd; Jan M Eberth; Andrew B Lawson; Swann Arp Adams; Eric Adjei Boakye; Melanie S Jefferson; Caitlin G Allen; John L Pearce; Hong Li; Chanita Hughes Halbert Journal: Int J Environ Res Public Health Date: 2021-11-11 Impact factor: 3.390
Authors: Jie Shen; Bernard F Fuemmeler; Vanessa B Sheppard; Harry D Bear; Renduo Song; Wong-Ho Chow; Hua Zhao Journal: Sci Rep Date: 2022-06-30 Impact factor: 4.996
Authors: Paige Neroda; Mei-Chin Hsieh; Xiao-Cheng Wu; Kathleen B Cartmell; Rachel Mayo; Jiande Wu; Chindo Hicks; Lu Zhang Journal: Front Public Health Date: 2021-06-02